A Population Pharmacokinetic Model for 51 Cr EDTA to Estimate Renal Function
Cr EDTA clearance (CL) from plasma is used to estimate glomerular filtration rate (GFR). We propose that current methods for analysing the raw Cr EDTA measurements over-simplifies the disposition of Cr EDTA and therefore could produce biased GFR estimates. The aim of this study was to develop a popu...
Saved in:
Published in | Clinical pharmacokinetics Vol. 56; no. 6; p. 671 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
01.06.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cr EDTA clearance (CL) from plasma is used to estimate glomerular filtration rate (GFR). We propose that current methods for analysing the raw
Cr EDTA measurements over-simplifies the disposition of
Cr EDTA and therefore could produce biased GFR estimates. The aim of this study was to develop a population pharmacokinetic model for
Cr EDTA disposition and to compare model-predicted GFR to other methods of estimating renal function.
Data from 40 individuals who received ~7.4 MBq of
Cr EDTA, as an intravenous bolus, were available for analysis. Plasma radioactivity (counts/min) was measured from timed collection points at 2, 4, 6 and 24 h after the dose. A population analysis was conducted using NONMEM
version 7.2. Model-predicted GFR was compared with other methods for estimating renal function using mean prediction error (MPE).
A two-compartment pharmacokinetic model with first-order elimination best fit the data. Compared with the model predictions, creatinine CL from 24 h urine data was unbiased. The commonly used 'slope-intercept' method for estimating isotopic GFR was positively biased compared with the model (MPE 15.5 mL/min/1.73 m
[95% confidence interval {CI} 8.9-22.2]. The Cockcroft Gault, Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equations led to negatively biased GFR estimates (MPE -19.0 [95% CI -25.4 to -12.7], -20.1 [95% CI -27.2 to -13.1] and -16.5 [95% CI -22.2 to -10.1] mL/min/1.73 m
, respectively).
The biased GFR estimates were most obvious in patients with relatively normal renal function. This may lead to inaccurate dosing in patients who are receiving drugs with a narrow therapeutic range where dosing is adjusted according to GFR estimates (e.g. carboplatin).
The study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), number: ACTRN 12611000035921. |
---|---|
AbstractList | Cr EDTA clearance (CL) from plasma is used to estimate glomerular filtration rate (GFR). We propose that current methods for analysing the raw
Cr EDTA measurements over-simplifies the disposition of
Cr EDTA and therefore could produce biased GFR estimates. The aim of this study was to develop a population pharmacokinetic model for
Cr EDTA disposition and to compare model-predicted GFR to other methods of estimating renal function.
Data from 40 individuals who received ~7.4 MBq of
Cr EDTA, as an intravenous bolus, were available for analysis. Plasma radioactivity (counts/min) was measured from timed collection points at 2, 4, 6 and 24 h after the dose. A population analysis was conducted using NONMEM
version 7.2. Model-predicted GFR was compared with other methods for estimating renal function using mean prediction error (MPE).
A two-compartment pharmacokinetic model with first-order elimination best fit the data. Compared with the model predictions, creatinine CL from 24 h urine data was unbiased. The commonly used 'slope-intercept' method for estimating isotopic GFR was positively biased compared with the model (MPE 15.5 mL/min/1.73 m
[95% confidence interval {CI} 8.9-22.2]. The Cockcroft Gault, Modification of Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equations led to negatively biased GFR estimates (MPE -19.0 [95% CI -25.4 to -12.7], -20.1 [95% CI -27.2 to -13.1] and -16.5 [95% CI -22.2 to -10.1] mL/min/1.73 m
, respectively).
The biased GFR estimates were most obvious in patients with relatively normal renal function. This may lead to inaccurate dosing in patients who are receiving drugs with a narrow therapeutic range where dosing is adjusted according to GFR estimates (e.g. carboplatin).
The study is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), number: ACTRN 12611000035921. |
Author | Wright, Daniel F B Kuan, Isabelle H S Putt, Tracey L Duffull, Stephen B Schollum, John B W Walker, Robert J |
Author_xml | – sequence: 1 givenname: Isabelle H S surname: Kuan fullname: Kuan, Isabelle H S organization: School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand – sequence: 2 givenname: Stephen B surname: Duffull fullname: Duffull, Stephen B organization: School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand – sequence: 3 givenname: Tracey L surname: Putt fullname: Putt, Tracey L organization: Department of Medicine, University of Otago, Dunedin, New Zealand – sequence: 4 givenname: John B W surname: Schollum fullname: Schollum, John B W organization: Department of Medicine, University of Otago, Dunedin, New Zealand – sequence: 5 givenname: Robert J surname: Walker fullname: Walker, Robert J organization: Department of Medicine, University of Otago, Dunedin, New Zealand – sequence: 6 givenname: Daniel F B surname: Wright fullname: Wright, Daniel F B email: dan.wright@otago.ac.nz organization: School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand. dan.wright@otago.ac.nz |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27943221$$D View this record in MEDLINE/PubMed |
BookMark | eNqFjUELgjAYQEcUqdVfiO8PCNuszKOY0qFAwrssnbSam2zz0L-voM6d3uU9XoCmSis-QT4hcRKShO48FFh7xxjvKcZz5NE42USUEh-dUij1MErmhFZQ3pjpWaMfQnEnGjjrlkvotIEtgcxAfqhScBpy60TPHIcLV0xCMarm0y_RrGPS8tWXC7Qu8io7hsN47XlbD-ZdmWf920d_hRdD0jrY |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE MEDLINE with Full Text Medline Complete PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1179-1926 |
ExternalDocumentID | 27943221 |
Genre | Controlled Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -5G -BR -EM .GJ .XZ 0R~ 0VX 199 29B 2JY 34G 36B 39C 3V. 4.4 406 53G 5GY 5RE 6I2 6J9 6PF 7X7 88E 8FI 8FJ 8R4 8R5 8UJ 95. AAAUJ AABHQ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AANZL AARHV AASML AATNV AAWTL AAYQN AAYTO AAYZH ABAKF ABDZT ABFTV ABIPD ABJNI ABJOX ABKCH ABKMS ABKTR ABOCM ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFO ACGFS ACMJI ACMLO ACOKC ACREN ACZOJ ADBBV ADFRT ADFZG ADHHG ADJJI ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEYRQ AFALF AFBBN AFFNX AFKRA AFWTZ AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN AIZAD AJRNO ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AVWKF AWSVR AXYYD AZFZN A~4 BENPR BGNMA BPHCQ BVXVI CAG CCPQU CGR COF CS3 CUY CVF DCUDU DNIVK DPUIP DU5 EBLON EBS ECM EIF EJD EMOBN ESX F5P F8P FERAY FIGPU FLLZZ FNLPD FSGXE FYUFA HF~ HMCUK IAO IEA IHR IMOTQ INH INR ITC IWAJR J-C JZLTJ LGEZI LLZTM LOTEE M1P M4Y NADUK NPM NQJWS NU0 NXXTH OAC OPC OVD P2P PQQKQ PROAC PSQYO Q2X ROL RSV RZALA SISQX SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW TEORI TSG U5U U9L UAX UG4 UKHRP UNMZH UTJUX VDBLX VFIZW W48 WAF YQY Z0Y Z7U ZGI ZMTXR ZXP ~JE |
ID | FETCH-pubmed_primary_279432213 |
IngestDate | Wed Oct 16 00:57:51 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_279432213 |
PMID | 27943221 |
ParticipantIDs | pubmed_primary_27943221 |
PublicationCentury | 2000 |
PublicationDate | 2017-06-00 |
PublicationDateYYYYMMDD | 2017-06-01 |
PublicationDate_xml | – month: 06 year: 2017 text: 2017-06-00 |
PublicationDecade | 2010 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Clinical pharmacokinetics |
PublicationTitleAlternate | Clin Pharmacokinet |
PublicationYear | 2017 |
References | 18076358 - Clin Chem Lab Med. 2008;46(2):215-8 12432431 - Pediatr Nephrol. 2002 Nov;17(11):903-7 16794818 - Pediatr Nephrol. 2006 Sep;21(9):1299-306 25135059 - Eur J Clin Pharmacol. 2014 Oct;70(10):1221-6 22624135 - N Am J Med Sci. 2010 Apr;2(4):170-3 16176118 - Clin Pharmacokinet. 2005;44(10):1051-65 19833901 - J Am Soc Nephrol. 2009 Nov;20(11):2305-13 16908915 - Ann Intern Med. 2006 Aug 15;145(4):247-54 4980763 - Clin Sci. 1969 Aug;37(1):169-80 15266169 - Nucl Med Commun. 2004 Aug;25(8):759-69 2681557 - J Clin Oncol. 1989 Nov;7(11):1748-56 10075613 - Ann Intern Med. 1999 Mar 16;130(6):461-70 16112041 - Am J Kidney Dis. 2005 Aug;46(2):233-41 4164301 - Lancet. 1967 Apr 15;1(7494):818-9 19414839 - Ann Intern Med. 2009 May 5;150(9):604-12 20299365 - Clin J Am Soc Nephrol. 2010 Jun;5(6):1003-9 24026245 - Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv122-30 4629674 - Scand J Clin Lab Invest. 1972 Nov;30(3):271-4 4625784 - Arch Dis Child. 1972 Aug;47(254):613-7 19055616 - Transpl Int. 2009 Mar;22(3):323-31 1244564 - Nephron. 1976;16(1):31-41 11207037 - Br J Cancer. 2001 Feb;84(4):452-9 14710207 - Br J Cancer. 2004 Jan 12;90(1):60-4 21611079 - Clin Biochem Rev. 2011 May;32(2):69-73 4986443 - Scand J Clin Lab Invest. 1969 Jun;23(4):301-5 15961546 - Clin Chem. 2005 Aug;51(8):1420-31 11315614 - Eur J Nucl Med. 2001 Mar;28(3):BP31-6 7310648 - J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12 6421537 - Clin Physiol. 1984 Feb;4(1):61-74 |
References_xml | |
SSID | ssj0008200 |
Score | 4.091367 |
Snippet | Cr EDTA clearance (CL) from plasma is used to estimate glomerular filtration rate (GFR). We propose that current methods for analysing the raw
Cr EDTA... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 671 |
SubjectTerms | Adult Aged Aged, 80 and over Chromium Radioisotopes Edetic Acid - blood Edetic Acid - pharmacokinetics Female Glomerular Filtration Rate Humans Kidney - physiology Kidney Diseases - blood Kidney Diseases - physiopathology Male Models, Biological Young Adult |
Title | A Population Pharmacokinetic Model for 51 Cr EDTA to Estimate Renal Function |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27943221 |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ27b8IwEMatQpcuVd9vdEPFEoLIk6zhJVq1KEMqsaE4JEtVQCEM9K_v2Y7jFBWp7RKhBFnAj9iX8933EfLYYYIh3NCE9X7gE4Ore2ls6JHVpa5L05RyAdPXiTt-s5-nzlQ5FfLukpy2488f-0r-QxXPIVfWJfsHsuWgeAJfI188ImE8_oqxrwWl_5YWFCLU7xg3MhVW5nLGmxM1x9D6mTYchD6LNId4U2OYyvwaWCQ6woWthCMlC2S75Or7mJWNH5E3fVpHbOMi0cYqhTrYpCynXykhU87OwUbsReEKGeNkVCaemRaotFzmtTw9Ufgn8xFGV9VNtRMxh-I9rmPg6FYnWaEeXvyZqjOmKxxYKrRWHxyXyaTrTNNQC1VZPigv1UjNMpw6OfRHvd6kXIAxqGEGf_JdOw8MPHAIT8hxEfGDL_CdkoNkcUaaBa1tC0LVAbduQRMCJSa-PScvPijGsMMYOGNAxuAY0M-AMYZ8CZIxcMYgGV-QxmgY9se6-KSzlZAamcnvYF2S-mK5SK4JdDuR4849Zshu2pZtUjtOvXmaRB6lpj03b8jVnkFu9165I0cK5T2p59kmecBgK6eN4sf9ArOvMYM |
link.rule.ids | 315,786,790 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Population+Pharmacokinetic+Model+for+51+Cr+EDTA+to+Estimate+Renal+Function&rft.jtitle=Clinical+pharmacokinetics&rft.au=Kuan%2C+Isabelle+H+S&rft.au=Duffull%2C+Stephen+B&rft.au=Putt%2C+Tracey+L&rft.au=Schollum%2C+John+B+W&rft.date=2017-06-01&rft.eissn=1179-1926&rft.volume=56&rft.issue=6&rft.spage=671&rft_id=info%3Apmid%2F27943221&rft.externalDocID=27943221 |